@article{863d16b476134a52976f625becf7be29,
title = "New cancers after autotransplantations for multiple myeloma",
abstract = "We describe baseline incidence and risk factors for new cancers in 4161 persons receiving autotransplants for multiple myeloma in the United States from 1990 to 2010. Observed incidence of invasive new cancers was compared with expected incidence relative to the US population. The cohort represented 13,387 person-years at-risk. In total, 163 new cancers were observed, for a crude incidence rate of 1.2 new cancers per 100 person-years and cumulative incidences of 2.6% (95% confidence interval [CI], 2.09 to 3.17), 4.2% (95% CI, 3.49 to 5.00), and 6.1% (95% CI, 5.08 to 7.24) at 3, 5, and 7years, respectively. The incidence of new cancers in the autotransplantation cohort was similar to age-, race-, and gender-adjusted comparison subjects with an observed/expected (O/E) ratio of 1.00 (99% CI, .81 to 1.22). However, acute myeloid leukemia and melanoma were observed at higher than expected rates with O/E ratios of 5.19 (99% CI, 1.67 to 12.04; P=0004), and 3.58 (99% CI, 1.82 to 6.29; P < .0001), respectively. Obesity, older age, and male gender were associated with increased risks of new cancers in multivariate analyses. This large data set provides a baseline for comparison and defines the histologic type specific risk for new cancers in patients with MM receiving postautotransplantation therapies, such as maintenance.",
keywords = "Myeloma, Second cancer, Transplantation",
author = "Anuj Mahindra and Girindra Raval and Paulette Mehta and Ruta Brazauskas and Zhang, {Mei Jie} and Xiaobo Zhong and Bird, {Jennifer M.} and Freytes, {C{\'e}sar O.} and Hale, {Gregory A.} and Roger Herzig and Holmberg, {Leona A.} and Kamble, {Rammurti T.} and Shaji Kumar and Lazarus, {Hillard M.} and Majhail, {Navneet S.} and Marks, {David I.} and Moreb, {Jan S.} and Richard Olsson and Wael Saber and Savani, {Bipin N.} and Schiller, {Gary J.} and Jason Tay and Vogl, {Dan T.} and Waller, {Edmund K.} and Wiernik, {Peter H.} and Baldeep Wirk and Sagar Lonial and Krishnan, {Amrita Y.} and Angela Dispenzieri and Brandenburg, {Nancy A.} and Gale, {Robert Peter} and Hari, {Parameswaran N.}",
note = "Funding Information: A new cancer was defined as a previously unidentified invasive cancer occurring after transplantation. Carcinomas in situ and other precancerous abnormalities (eg, squamous intraepithelial neoplasia) were excluded. Pathology reports were obtained and reviewed centrally to confirm the diagnosis. Transplantation centers were contacted to resolve ambiguities. After confirmation, diagnoses of new cancers were coded by ICD-O-3 for comparison with the US National Cancer Institute's Surveillance, Epidemiology, and End Results program (SEER) [9] . SEER consists of high-quality, population-based cancer registries that are supported and sponsored by the National Cancer Institute. The SEER program is the authoritative source on invasive cancer incidence and survival in the United States. Publisher Copyright: {\textcopyright} 2015 American Society for Blood and Marrow Transplantation.",
year = "2015",
month = apr,
day = "1",
doi = "10.1016/j.bbmt.2014.12.028",
language = "English (US)",
volume = "21",
pages = "738--745",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "4",
}